Teva Pharmaceutical Industries Ltd. announced the launch of a generic version of AndroGel ®i (testosterone gel) 1.62% CIII in the U.S.
Testosterone Gel 1.62% CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: primary hypogonadism (congenital or acquired), and hypogonadotropic hypogonadism (congenital or acquired).
With nearly 500 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. Currently, one in eight generic prescriptions dispensed in the U.S. is filled with a Teva generic product.
Testosterone Gel 1.62% CIII has annual sales of more than $911 million in the U.S., according to IQVIA data as of February 2019.
